Global Kidney Cancer Diagnostics Market is projected to register a CAGR of 6.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Global Kidney Cancer Diagnostics Market, By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stages (Stage I , Stage II, Stage III, and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, and Non-Clear Cell Renal Cell Carcinoma), Product (Platform-Based Products, Instrument based products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research),End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, Europe, China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan and the rest of Asia-Pacific, South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel, the Rest of Middle East and Africa, Brazil, Argentina, and the Rest of South America), Industry Trends and Forecast to 2030.
.
Some of the major factors contributing to the growth of the kidney cancer diagnostics market are:
Rising healthcare expenditure for better health services
Rising Awareness about kidney cancer
Increase in diagnostic procedure for kidney cancer
Market Players
Some of the key market players for global kidney cancer diagnostics market are listed below:
Ambry Genetics
BD
BioVendor R&D
BluePrint Oy.
Canon Medical Systems Corporation
CD Genomics
CENTOGENE N.V.
Creative Diagnostics
FUJIFILM Corporation
GeneDx, LLC
GenPath
Grail
Illumina, Inc.
Invitae Corporation
Koninklijke Philips N.V.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
Qiagen
Seimens Healthcare GmbH
Thermo Fisher Scientific Inc.
TABLE OF CONTENTS
1 INTRODUCTION 85
- 1.1 OBJECTIVES OF THE STUDY 85
- 1.2 MARKET DEFINITION 85
- 1.3 OVERVIEW OF THE GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET 85
- 1.4 CURRENCY AND PRICING 87
- 1.5 LIMITATIONS 88
- 1.6 MARKETS COVERED 88
2 MARKET SEGMENTATION 92
- 2.1 MARKETS COVERED 92
- 2.2 GEOGRAPHICAL SCOPE 93
- 2.3 YEARS CONSIDERED FOR THE STUDY 94
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 95
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 98
- 2.6 MULTIVARIATE MODELLING 99
- 2.7 MARKET APPLICATION COVERAGE GRID 100
- 2.8 TEST TYPE LIFELINE CURVE 101
- 2.9 DBMR MARKET POSITION GRID 102
- 2.10 VENDOR SHARE ANALYSIS 103
- 2.11 SECONDARY SOURCES 104
- 2.12 ASSUMPTIONS 104
3 EXECUTIVE SUMMARY 105
4 PREMIUM INSIGHTS 108
- 4.1 PESTEL ANALYSIS 111
- 4.2 PORTER'S 5 FORCES 112
- 4.3 EPIDEMIOLOGY 113
- 4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES 114
- 4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES 114
5 INDUSTRY INSIGHTS 115
6 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS 117
7 MARKET OVERVIEW 120
- 7.1 DRIVERS 122
- 7.1.1 GROWING PREVALENCE OF KIDNEY CANCER 122
- 7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER 124
- 7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 125
- 7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER 125
- 7.2 RESTRAINTS 126
- 7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS 126
- 7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 127
- 7.3 OPPORTUNITIES 127
- 7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 127
- 7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS 128
- 7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 128
- 7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 129
- 7.4 CHALLENGES 129
- 7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 129
- 7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS 130
8 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE 131
- 8.1 OVERVIEW 132
- 8.2 IMAGING 136
- 8.2.1 COMPUTED TOMOGRAPHY 137
- 8.2.2 ULTRASOUND 137
- 8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 137
- 8.2.4 ANGIOGRAPHY 137
- 8.2.5 X-RAY 137
- 8.2.6 OTHERS 137
- 8.3 BLOOD TEST 137
- 8.4 BIOPSY 138
- 8.4.1 FINE NEEDLE ASPIRATION 139
- 8.4.2 NEEDLE CORE BIOPSY 139
- 8.5 BIOMARKER TEST 139
- 8.5.1 AQUAPORIN 1 (AQP1) 141
- 8.5.2 PERILIPIN (PLIN2) 141
- 8.5.3 N-METHYLTRANSFERASE (NMNT) 141
- 8.5.4 L-PLASTIN (LCP-1) 141
- 8.5.5 NM23A 141
- 8.6 GENETIC TEST 141
- 8.7 OTHERS 142
9 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 144
- 9.1 OVERVIEW 145
- 9.2 STAGE I 148
- 9.3 STAGE II 148
- 9.4 STAGE III 149
- 9.5 STAGE IV 150
10 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 151
- 10.1 OVERVIEW 152
- 10.2 RENAL CELL CARCINOMA 156
- 10.2.1 IMAGING 157
- 10.2.2 BLOOD TEST 157
- 10.2.3 BIOPSY 157
- 10.2.4 BIOMARKER TEST 157
- 10.2.5 GENETIC TEST 157
- 10.2.6 OTHERS 157
- 10.3 CLEAR CELL RENAL CELL CARCINOMA 157
- 10.3.1 IMAGING 159
- 10.3.2 BLOOD TEST 159
- 10.3.3 BIOPSY 159
- 10.3.4 BIOMARKER TEST 159
- 10.3.5 GENETIC TEST 159
- 10.3.6 OTHERS 159
- 10.4 NON CLEAR CELL RENAL CELL CARCINOMA 159
- 10.4.1 PAPILLARY RENAL CELL CARCINOMA 160
- 10.4.1.1 IMAGING 161
- 10.4.1.2 BLOOD TEST 161
- 10.4.1.3 BIOPSY 161
- 10.4.1.4 BIOMARKER TEST 161
- 10.4.1.5 GENETIC TEST 161
- 10.4.1.6 OTHERS 161
- 10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 161
- 10.4.2.1 IMAGING 162
- 10.4.2.2 BLOOD TEST 162
- 10.4.2.3 BIOPSY 162
- 10.4.2.4 BIOMARKER TEST 162
- 10.4.2.5 GENETIC TEST 162
- 10.4.2.6 OTHERS 162
11 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 163
- 11.1 OVERVIEW 164
- 11.2 INSTRUMENT BASED PRODUCTS 168
- 11.2.1 IMAGING 169
- 11.2.2 BIOPSY 169
- 11.3 PLATFORM BASED PRODUCTS 169
- 11.3.1 NEXT GENERATION SEQUENCING 171
- 11.3.2 MICROARRAYS 171
- 11.3.3 PCR 172
- 11.3.4 OTHERS 172
- 11.4 KITS AND REAGENTS 172
- 11.4.1 RENAL CANCER PANELS 174
- 11.4.2 RENAL CANCER ANTIBODIES 174
- 11.5 OTHER CONSUMABLES 174
12 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 175
- 12.1 OVERVIEW 176
- 12.2 FLUORESCENT IN SITU HYBRIDIZATION 179
- 12.3 NEXT GENERATION SEQUENCING 179
- 12.4 FLUORIMMUNOASSAY 180
- 12.5 COMPARATIVE GENOMIC HYBRIDIZATION 181
- 12.6 IMMUNOHISTOCHEMICAL 182
- 12.7 OTHERS 182
13 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 184
- 13.1 OVERVIEW 185
- 13.2 SCREENING 188
- 13.2.1 INSTRUMENT BASED PRODUCTS 189
- 13.2.2 PLATFORM BASED PRODUCTS 189
- 13.2.3 KITS AND REAGENTS 189
- 13.2.4 OTHER CONSUMABLES 189
- 13.3 DIAGNOSTIC AND PREDICTIVE 189
- 13.3.1 INSTRUMENT BASED PRODUCTS 190
- 13.3.2 PLATFORM BASED PRODUCTS 190
- 13.3.3 KITS AND REAGENTS 190
- 13.3.4 OTHER CONSUMABLES 190
- 13.4 PROGNOSTIC 191
- 13.4.1 INSTRUMENT BASED PRODUCTS 192
- 13.4.2 PLATFORM BASED PRODUCTS 192
- 13.4.3 KITS AND REAGENTS 192
- 13.4.4 OTHER CONSUMABLES 192
- 13.5 RESEARCH 192
- 13.5.1 INSTRUMENT BASED PRODUCTS 193
- 13.5.2 PLATFORM BASED PRODUCTS 193
- 13.5.3 KITS AND REAGENTS 193
- 13.5.4 OTHER CONSUMABLES 194
14 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER 195
- 14.1 OVERVIEW 196
- 14.2 HOSPITALS 199
- 14.3 DIAGNOSTIC CENTERS 199
- 14.4 CANCER RESEARCH CENTERS 200
- 14.5 ACADEMIC INSTITUTES 201
- 14.6 AMBULATORY SURGICAL CENTERS 201
- 14.7 OTHERS 202
15 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 203
- 15.1 OVERVIEW 204
- 15.2 DIRECT TENDER 207
- 15.3 RETAIL SALES 207
- 15.4 OTHERS 208
16 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION 209
- 16.1 OVERVIEW 210
- 16.2 NORTH AMERICA 216
- 16.2.1 U.S. 230
- 16.2.2 CANADA 239
- 16.2.3 MEXICO 248
- 16.3 ASIA-PACIFIC 257
- 16.3.1 CHINA 270
- 16.3.2 JAPAN 277
- 16.3.3 INDIA 284
- 16.3.4 SOUTH KOREA 291
- 16.3.5 AUSTRALIA 298
- 16.3.6 TAIWAN 305
- 16.3.7 NEW ZEALAND 313
- 16.3.8 INDONESIA 320
- 16.3.9 THAILAND 327
- 16.3.10 PHILIPPINES 334
- 16.3.11 MALAYSIA 341
- 16.3.12 VIETNAM 348
- 16.3.13 SINGAPORE 355
- 16.3.14 REST OF ASIA PACIFIC 362
- 16.4 EUROPE 363
- 16.4.1 GERMANY 379
- 16.4.2 FRANCE 388
- 16.4.3 UNITED KINGDOM 397
- 16.4.4 ITALY 406
- 16.4.5 SPAIN 415
- 16.4.6 RUSSIA 424
- 16.4.7 NETHERLANDS 433
- 16.4.8 POLAND 442
- 16.4.9 SWITZERLAND 451
- 16.4.10 BELGIUM 460
- 16.4.11 SWEDEN 469
- 16.4.12 NORWAY 478
- 16.4.13 DENMARK 487
- 16.4.14 FINLAND 496
- 16.4.15 TURKEY 505
- 16.4.16 REST OF EUROPE 514
- 16.5 SOUTH AMERICA 515
- 16.5.1 BRAZIL 527
- 16.5.2 ARGENTINA 534
- 16.5.3 REST OF SOUTH AMERICA 542
- 16.6 MIDDLE EAST AND AFRICA 543
- 16.6.1 SOUTH AFRICA 556
- 16.6.2 SAUDI ARABIA 563
- 16.6.3 BAHRAIN 571
- 16.6.4 U.A.E. 578
- 16.6.5 EGYPT 586
- 16.6.6 ISRAEL 594
- 16.6.7 KUWAIT 602
- 16.6.8 OMAN 610
- 16.6.9 QATAR 618
- 16.6.10 REST OF MIDDLE EAST AND AFRICA 626
17 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 627
- 17.1 COMPANY SHARE ANALYSIS: GLOBAL 627
- 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 628
- 17.3 COMPANY SHARE ANALYSIS: EUROPE 629
- 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 630
18 SWOT ANALYSIS 631
19 COMPANY PROFILE 632
- 19.1 CANON MEDICAL SYSTEMS CORPORATION 632
- 19.1.1 COMPANY SNAPSHOT 632
- 19.1.2 REVENUE ANALYSIS 632
- 19.1.3 COMPANY PROFILE 633
- 19.1.4 PRODUCT PORTFOLIO 633
- 19.1.5 RECENT DEVELOPMENT 633
- 19.2 KONINKLIJKE PHILIPS N.V. 634
- 19.2.1 COMPANY SNAPSHOT 634
- 19.2.2 REVENUE ANALYSIS 634
- 19.2.3 COMPANY PROFILE 635
- 19.2.4 PRODUCT PORTFOLIO 635
- 19.2.5 RECENT DEVELOPMENTS 636
- 19.3 GENERAL ELECTRIC COMPANY 637
- 19.3.1 COMPANY SNAPSHOT 637
- 19.3.2 REVENUE ANALYSIS 637
- 19.3.3 COMPANY PROFILE 638
- 19.3.4 PRODUCT PORTFOLIO 638
- 19.3.5 RECENT DEVELOPMENTS 639
- 19.4 SIEMENS HEALTHCARE GMBH 640
- 19.4.1 COMPANY SNAPSHOT 640
- 19.4.2 REVENUE ANALYSIS 640
- 19.4.3 COMPANY PROFILE 641
- 19.4.4 PRODUCT PORTFOLIO 641
- 19.4.5 RECENT DEVELOPMENT 642
- 19.5 GRAIL 643
- 19.5.1 COMPANY SNAPSHOT 643
- 19.5.2 PRODUCT PORTFOLIO 643
- 19.5.3 RECENT DEVELOPMENTS 643
- 19.6 AMBRY GENETICS 645
- 19.6.1 COMPANY SNAPSHOT 645
- 19.6.2 PRODUCT PORTFOLIO 645
- 19.6.3 RECENT DEVELOPMENT 645